Journal of Hepatology
Volume 49, Issue 4 , Pages 557-563 , October 2008

Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma

  • Vincenzo La Mura

      Affiliations

    • Internal Medicine and Hepatology Unit, Second University of Naples, Via F. Petrarca 101/b, 80122 Napoli, Italy
    • ,
  • Amalia De Renzo

      Affiliations

    • Hematology Unit, Federico II University, Naples, Italy
    • ,
  • Fabiana Perna

      Affiliations

    • Hematology Unit, Federico II University, Naples, Italy
    • ,
  • Diego D’Agostino

      Affiliations

    • Department of Molecular and Clinical Oncology and Endocrinology, Federico II University, Naples, Italy
    • ,
  • Mario Masarone

      Affiliations

    • Internal Medicine and Hepatology Unit, Second University of Naples, Via F. Petrarca 101/b, 80122 Napoli, Italy
    • ,
  • Marco Romano

      Affiliations

    • Unit of Gastroenterology, Second University of Naples, Naples, Italy
    • ,
  • Savino Bruno

      Affiliations

    • Department of Internal Medicine, Fatebenefratelli Hospital, Milano, Italy
    • ,
  • Roberto Torella

      Affiliations

    • Internal Medicine and Hepatology Unit, Second University of Naples, Via F. Petrarca 101/b, 80122 Napoli, Italy
    • ,
  • Marcello Persico

      Affiliations

    • Internal Medicine and Hepatology Unit, Second University of Naples, Via F. Petrarca 101/b, 80122 Napoli, Italy
    • Corresponding Author InformationCorresponding author. Tel./fax: +39 0815666838.

Received 17 March 2008 ,Revised 9 June 2008 ,Accepted 25 June 2008.

References 

  1. Agnello V, De Rosa MG. Extrahepatic manifestations of HCV infection: some current issues. J Hepatol. 2004;40:341–352
  2. Musto P. Hepatitis C virus and B-cell Non Hodjkin’s lymphomas: more than a simple association. Clin Lymphoma. 2002;3:150–160
  3. Morgensztern D, Rosado M, Silva O, Santos E, Abdullah S, Goodman M, et al. Prevalence of hepatitis C infection in patients with non-Hodgkin’s lymphoma in South Florida and review of the literature. Leuk Lymphoma. 2004;45:2459–2464
  4. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131:1879–1886
  5. De Vita S, De Re V, Sansonno D, Gloghini A, Gasparotto D, Libra M, et al. Lack of HCV infection in malignat cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori. 2002;88:400–406
  6. Persico M, Capasso M, Persico E, Masarone M, De Renzo A, Spano D, et al. Interleukin-10-1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol. 2006;45:779–785
  7. Negri E, Little D, Baiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004;10:1–8
  8. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodjkin’s lymphoma: a meta analysis of epidemiological studies. Cancer Sci. 2004;95:745–752
  9. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120:1034–1041
  10. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Peg-interferon alfa 2b plus ribavirin compared with interferon-alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  11. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94
  12. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, Non-Hodjkin’s lymphoma: a multicenter italian experience. J Clin Oncol. 2005;23:468–473
  13. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin’s Lymphoma. N Engl J Med. 1993;328:1002–1006
  14. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med. 2002;346:235–242
  15. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–1117
  16. Cheson BD. What is new in lymphoma?. CA A Cancer J Clin. 2004;54:260–272
  17. Mele A, Pulsioni A, Bianco E, Musto P, Szklo A, San Paolo MG, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multiceter case-control study. Blood. 2003;103:996–999
  18. De Rosa G, Gobbo ML, De Renzo A, Notaro R, Garofalo S, Grimaldi M, et al. Prevalence of Hepatitis C Virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55:77–82
  19. Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C. Involvement of PI·K in HCV-related lymphoproliferative disorders. J Cell Physiol. 2008;214:396–404
  20. Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infect Dis. 2003;26:115–124
  21. Zignego A, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol. 2007;13:2467–2478
  22. Tomita N, Kodama F, Takabayashi M, Kawano T, Yamaji S, Fujimaki K, et al. Clinical features and outcome in HCV-positive aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1159–1164
  23. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med. 2002;137:571–580
  24. Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood. 2003;102:1196–1201
  25. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17:1434–1440
  26. Groupe d’Etude des Lymphomes de l’Adulte Programs. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98. J Clin Oncol 2006; 24: 953–960.

☆ The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the drugs involved either in the past or present and they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00435-2

doi: 10.1016/j.jhep.2008.06.025

Journal of Hepatology
Volume 49, Issue 4 , Pages 557-563 , October 2008

Article Tools

* Image Usage & Resolution